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Abstract
Synthetic transcriptional networks built from CRISPR-based repressors (CRISPRi)
rely on shared use of a core dCas9 protein. In E. coli, CRISPRi cannot sup-
port more than about a dozen simultaneous gRNAs before the fold repression
of any individual gRNA drops below 10x. We show with a simple model based
on previous characterization of competition in CRISPRi that activation by
CRISPR-based activators (CRISPRa) is much less sensitive to dCas9 bottle-
necking than CRISPRi. We predict that E. coli should be able to support
dozens to hundreds of CRISPRa gRNAs at >10-fold activation.
1. Introduction
One of the most powerful and flexible tools in the modern synthetic biol-
ogist’s toolkit is the synthetic transcription factor network, which computes
and actuates using cascades of activation or repression by either naturally-
occurring or engineered transcription factors. Synthetic variants of transcrip-
tion factor networks have been used to build molecular oscillators [1, 2, 3, 4],
molecular fold change detectors [5, 6], signal level discriminators [7], and
simple, composable elementary logic units for both analog [7] and digital
[8, 9, 10, 11] computation.
To date, however, synthetic transcription factor networks remain limited
in size, with the largest circuits containing on order of a dozen transcription
factors [9, 10]. Several constraints limit the size of these networks. We focus
on two such constraints here:
• Difficulties of part design: Put simply, transcription factors are
hard to make. Traditional, wild-mined transcription factors like TetR,
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LacI, LasR, AraC, etc., are invaluable for small-scale prototyping, but
it is difficult to find large sets of transcription factors with compati-
ble operating concentrations and no crosstalk (the largest known set
currently consists of the 12 mutually-orthogonal transcription factors
in [9]). In principle, an almost arbitrary number of transcription fac-
tors could be built using zinc finger nuclease (ZFN) or transcription
activator-like effector nuclease (TALEN) technology, but in practice,
high-quality ZFNs are difficult to engineer and TALENs are prone to
recombination and mutational breakage.
• Difficulties of limited resources: Transcription factor networks use
up cell resources (ATP, amino acid, ribosomes, etc.). Particularly in
bacteria and other small, resource-limited cells, this load can cause
unexpected “retroactivity” feedback between nominally-unconnected
circuit components [12, 13]. Resource limits are particularly problem-
atic when they interfere with host cell growth, leading to evolutionary
pressure to disable the offending circuit [14, 15].
One promising development in synthetic transcription factor design is
the use of mutationally-inactivated Cas9 programmable nucleases [16] as
either repressors (CRISPRi; [16, 17, 18, 10, 19]) or activators (CRISPRa;
[18, 20, 21, 22, 23]). The simplest example of a CRISPR transcription
factor (CRISPRtf) is dCas9, which is Cas9 with two mutations that dis-
able its ability to cut DNA. When targeted to a promoter by a guide RNA
(gRNA), dCas9 strongly binds to the promoter, blocking RNA polymerase
attachment or transcriptional elongation (at least, in prokaryotes). Other
CRISPRtfs have been made by either fusing native polymerase-recruiting
factors to dCas9 or by recruiting those factors to a binding domain on the
gRNA. These synthetic transcription factors can be easily modified to create
new, orthogonal versions by simply changing the sequences of the binding
site and gRNA.
CRISPRtfs are easy to generate and have been used to successfully ma-
nipulate host gene expression [8] and to build limited-scale synthetic tran-
scriptional circuits [10]. However, while CRISPRtfs largely bypass difficulties
of part design, they introduce a new barrier to scalability in the form of a
troublesome resource bottleneck – dCas9 or dCas9 fusion protein. Any ex-
pression of one gRNA in a network of CRISPRtfs sequesters shared dCas9
away from other gRNAs, decreasing their effectiveness as outlined in detail
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in [24]. The dCas9 bottleneck can be loosened by producing more dCas9,
but this strategy is limited by the toxicity of dCas9 when expressed at high
concentration, especially in prokaryotes [25, 26].
In [27], Zhang and Voigt quantify this bottlenecking effect in E. coli They
show that under physiological, circuit-like conditions, dCas9 bottlenecking
causes CRISPRi target repression to drop off as roughly 1
N
, where N is the
number of competing gRNAs expressed. Furthermore, they show that E.
coli expressing near-maximal sustainable levels of dCas9 repressor cannot
support more than about ∼ 7 simultaneous gRNAs at a 10-fold level of
repression (or about ∼ 15 simultaneous gRNAs using a low-toxicity dCas9
variant, dCas9∗-PhlF).
Prior to 2018, CRISPRtfs in bacteria were largely limited to repressors,
as existing CRISPR activators typically exhibited ≤ 10-fold activation and
only functioned in an unusual, RpoZ -knockout strain; accordingly, the Zhang
and Voigt’s analysis of resource bottlenecking reasonably considered only
CRISPRi. There are now more effective CRISPRa activators made from SoxS
fusion proteins that do not require RpoZ knockout, which makes CRISPRa
a feasible alternative to CRISPRi for synthetic gene circuit construction [23].
In this paper, we use a simple model of gRNA competition for dCas9 to
show that CRISPR activators are substantially less vulnerable than CRISPR
repressors to dCas9 bottlenecking. Our model anticipates that CRISPRa
should be able to support many times more simultaneous gRNAs than CRISPRi
under most conditions, although CRISPRi may be more effective for very
small networks under ideal conditions.
2. Why activators are less sensitive to bottlenecking than repres-
sors
CRISPR activators should scale better than CRISPR repressors because,
in general, activators are more robust than repressors against removal of
regulator when they are already saturating.
Consider a repressor and an activator of equal strength and at high enough
concentration that every target promoter is bound. What happens if the
concentration of each regulator drops enough that one of the targets becomes
unbound? How much is each system affected? We could equivalently consider
the fraction of time bound for a single-target system, but for conceptual
simplicity, we will consider a system with a “large number” (say, > 5) of
targets that are each either bound or not.
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Figure 1: Changes in expression when the concentrations of two regulators (an activator
and a repressor) are changed under different regulator concentration regimes. Both the
repressor and the activator change expression 10-fold (top table). At low saturation of
target promoter by the regulators, the activated promoter is more sensitive to changes
in regulator concentration than the regulated promoter (middle table). Conversely, at
high target saturation, the activated promoter is more robust to changes in regulator
concentration (bottom table).
When one activator drops off a target, total expression falls by a little
less than a fraction 1
N
of maximum expression, where N is the number of
target promoters. The fold change in expression caused in this decrease in




N−1 = 1 +
1
N−1 . If N is reasonably
large, this fold change will be quite small (consider N = 10).
When all target promoters are bound by repressors, the total expression
of the bound promoters is 1
R
, where R is the fold-repression caused by a
single repressor binding to a single promoter. When a single repressor is
removed, the change (increase, this time) in expression is, again, roughly 1
N
,
but this change occurs against a background of “leak” experienced when all
repressors are bound (which is hopefully a small value) rather than maximum
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possible promoter expression (which is hopefully a larger value). The fold







= 1 + F
N
. This fold
change is only small if the number of targets is large compared to the fold-
repression of the repressor, and for most reasonably capable repressors in
most reasonably-sized cells it should be at least 2-fold.
Viewed another way, the changes in expression experienced when a small
amount of activator or repressor are removed are of roughly the same abso-
lute magnitude, but the relative impacts of those effect are quite different –
for an activator, the change should be compared against maximum expres-
sion (which should be large), whereas for a repressor, the change should be
compared against promoter leak (which should be small). Figure 1 shows
this difference for a concrete example of a 10-fold activator and a 10-fold
repressor targeting a 5-copy promoter.
Note that the asymmetry between sensitivities of activators and repressors
reverses itself at low concentrations of regulator – there, activators are more
sensitive to regulator changes and repressors are more robust. Compare
Figure 1, middle and bottom rows. Activators trade off high sensitivity
to concentration changes at low saturation for robustness to concentration
changes at high saturation, while repressors make the opposite tradeoff.
3. Simulations show that CRISPRa scales better than CRISPRi
Using a steady-state solution for a simple ODE model of CRISPR, we nu-
merically investigated the effects of gRNA competition on minimal CRISPRi
and CRISPRa systems consisting of a repressing or activating dCas9:gRNA
complex targeting a reporter gene. See section 5 for a description of the
model and details on how we calculate fold change.
We calculate fold change for three different concentrations of target pro-
moter roughly representing a genomically-integrated reporter, a reporter on
a low-copy plasmid, and a reporter on a high-copy plasmid (Fig. 2A, B, and
C, respectively). We use parameters estimated for this model from in vivo
data by Zhang & Voigt ([27]). We vary the concentration of dCas9 from 100
nM up to 530 nM, which is roughly the maximum concentration of dCas9
the E. coli used by Zhang & Voigt can support before suffering significant
growth defects.
The same model that (correctly) predicts that the scalability of CRISPRi
is severely hampered by inter-gRNA competition also predicts that CRISPRa
should be far more robust against inter-gRNA competition.
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Figure 2: Simulated fold change of activation with CRISPRa (green) or repression with
CRISPRi (perfect repression, orange; or 50x repression, purple) with various dCas9 con-
centrations and either A) 1 nM, B) 10 nM, or C) 100 nM of target promoter. Parameters
taken from [27]. The horizontal line in each plot marks the10x fold change.
We also predict that CRISPRi may produce higher-fold changes than
CRISPRa at low numbers of competing guide RNAs, especially when dCas9
is abundant with respect to the target promoter. Note that this prediction is
a direct consequence of the assumption that dCas9 is a perfect repressor, but
a finite activator. This means that the effectiveness of CRISPRi repression
is unbounded above – as binding becomes more efficient, the fold change
of repression approaches infinity – while CRISPRa activation effectiveness
is bounded above at 50x. If we relax this assumption so that CRISPRi is
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A)
B) C)
Figure 3: Predicted maximum number of competing guide RNAs before competition re-
duces fold change to below 10x, for various dCas9 concentrations and A) 1 nM, B) 10 nM,
or C) 100 nM of target promoter. Parameters taken from [27]. “0 Max gRNA” means
that a single gRNA competitor is sufficient to drive fold change below 10x.
equally as “effective” as CRISPRa (i.e., it represses 50x when fully bound),
then it fails to exceed (or even match) the overall fold-repression of CRISPRa
at any number of competing gRNAs (Fig. 2, purple curves).
These results are not unduly sensitive to the particular parameters es-
timated in [27]. We computed maximum “acceptable” competing gRNA
number (the largest number of competing gRNAs that still allows 10 fold
regulation of the target) for 1,000 randomly sampled parameters (see Fig.
4 for results from 100 representative parameter sets; see figure legend for
details on parameter sampling). Although there was a significant degree of
variation in CRISPRa scalability across simulations, only rarely did we ob-
serve CRISPRa with worse scaling than any simulated CRISPRi system (Fig.
4B).
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We also performed local gradient-based sensitivity analysis on each pa-
rameter. See Section 5.3 for details.
A) B)
Figure 4: A) Predicted maximum number of competing guide RNAs that still allow 10-fold
regulation for 100 of the 1,000 tested CRISPRi/a systems with randomly sampled param-
eters. Thin lines represent single sampled parameter sets; bold lines represent averages
across all sampled parameter sets. Target copy number was held fixed at 10. Transcription
speed for competing gRNAs was held to a constant multiple of that of the primary gRNA
(changes in one transcription rate relative to another are equivalent to a compression or
expansion of the gRNA concentration axis). Fold-activation of the CRISPRa activator
was sampled from a normal distribution with mean 50x and a 20% standard deviation,
reflecting our high confidence in our estimates of that parameter from [23]. All other pa-
rameters were log-normally distributed around their best-estimate values, as determined
in [27], with a log10 standard deviation of 0.5, very roughly representing a half-order-of-
magnitude “50% confidence range”. B) The fraction of sampled parameter sets (out of
1,000) in which CRISPRa was predicted to perform better than any sampled CRISPRi, at
each possible dCas9 concentration (CRISPRi was never observed to perform better than
CRISPRa with the same parameters).
4. Discussion
There are good reasons to use CRISPRi instead of CRISPRa when build-
ing bacterial biocircuits, at least in the near future. CRISPRi requires fewer
moving parts, produces larger best-case fold changes (and unquestionably
higher fold changes in single-gRNA systems), and is less likely to drastically
interfere with host genetic expression, at least in E. coli, as current-generation
prokaryotic CRISPRa activators use modified versions of E. coli activators
that upregulate some native promoters.
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Repression is arguably also a more useful tool than activation. In par-
ticular, several simple, classic genetic circuits rely exclusively on repression
(e.g., the repressilator [1], the two-gene genetic toggle switch [30], NOR-gates
[10]).
Finally, CRISPRa is more difficult to use on natural genomic targets, as
it requires a PAM within a ∼10 bp window of an ideal position upstream of
the target promoter’s -35 box. For some genes, this target simply does not
exist.
Nevertheless, CRISPRa has a distinct advantage over CRISPRi – it should
be significantly less impacted by bottlenecking of core dCas9. CRISPRi ef-
fectiveness is predicted to drop precipitously for systems above about a dozen
gRNAs, while CRISPRa should still function in the presence of dozens-to-
hundreds of competing gRNAs.
As CRISPR-based synthetic circuits grow in scale and complexity past
about a dozen components, we anticipate that the usefulness of CRISPRi
will drop off precipitously, while CRISPRa should still function even in the
presence of dozens of competing gRNAs (at least, for circuits with low target
concentrations). We urge anyone who dreams of building large CRISPR-
based biocircuits to consider using CRISPRa.
5. The Model
We adapt the modeling framework derived in [24] and adapted by Zhang
and Voigt in their analysis of gRNA competition in CRISPRi. We recapitu-
late their analysis and extend it to CRISPRa.
5.1. A simple model of CRISPRi
Following the analysis in [27] (originally formulated by Chen, Qian, and
Del Vecchio in [24]), we will consider a model of dCas9 repression in which
a gRNA g1 is in competition with some number N of functionally identical,
non-targeting gRNAs for a fixed amount of core dCas9. We wish to calculate
the fold change of repression of the target of g1 as a function of N .
We model dCas9 as a Shea-Ackers repressor of cooperativity 1 and a
single binding site per promoter [28]. We can then write down the average
transcription rate of a target promoter as a sum of rates rf and rC of tran-
scription from free and dCas9-bound promoter, respectively, weighted by the
concentration of promoter in each of those states:
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Parameter Description Value Units
rf Transcription rate from free (unbound) promoter. various s
−1
rC Transcription rate from dCas-bound promoter various s
−1
K
Association constant for dCas:gRNA complex
binding to promoter.
2.9 nM−1sec−1
Ptot Total promoter concentration. various nM
α1 Transcription rate of g1 7.6× 10−3 nM/s
αx Transcription rate of competing gRNAs. 2.3× 10−2 nM/s
β δ
K1
, δ =(degradation plus dilution) rate for gRNAs. 3.0× 10−2 nM−1s−1
Ctot Total steady-state dCas pool. various nM
N Number of competing gRNAs (not including g1). various unitless
Table 1: Parameter notation and values used in this model. Where possible, values were
taken from fits to endpoint repression data in [27] (see Fig. 3 of that paper).
Variable Description
P Concentration of free promoter.
PC Concentration of promoter bound to dCas9 repressor or activator.
Cg1 Concentration of dCas9:g1 complex.
C Concentration of free dCas9 regulator.
Table 2: Dynamic variables used in our model.
r = rfP + rCPC (1)
where r is the average transcription rate from the target promoter. If
no gRNA is expressed, PC = 0 and equation 1 simplifies to r = rfPtot. We
assume that rC = 0 (i.e., repression by bound dCas9 is perfect, allowing no
leak), so when the gRNA is active, equation 1 simplifies to rfP , where P will
vary with dCas9 concentration, gRNA expression level, number of competing





Now we can solve RFC at steady-state. We assume total promoter con-
centration is held constant, so Ptot = P + PC . At steady state, there will be
flux balance between dCas9 binding to P and dCas9 unbinding from PC , so
PC = KCg1P , where K =
kf
kr
is the association constant of binding between
10
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rf (P +KCg1P )
rfP
= 1 +KCg1 (3)
Now we make the informal quasi-steady state assumption that total dCas9
concentration Ctot is a constant set upstream by dCas9 production rates and
dilution/degradation. Using a conservation law for dCas9 and steady-state
flux balance of dCas9 and guide RNAs, the steady-state concentration of
dCas9:g1 (Cs1) can be calculated as:
Cg1 =
α1Ctot
β + α1 +Nαx
− PC (4)
To find the steady-state concentration of PC , we use 1) flux-balance be-
tween bound and free promoter and 2) mass conservation of promoter:
PC = KCg1P (5)
Ptot = PC + P (6)





where, again, K is the association constant for binding between dCas9:gRNA
and promoter. Substituting this into (4) and rearranging yields a quadratic
polynomial in CS:




β + α1 +NαX
(9)
Cg1 is then well-specified algebraically, and can easily be computed nu-
merically.
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5.2. A simple model of CRISPRa
We apply a similar analysis to the case of an activating CRISPR system
under varying gRNA competition. The most salient changes from the analy-
sis in section 5.1 are 1) rC 6≈ 0 (and rf 6≈ 0), and 2) the fold change we wish
to calculate is the reciprocal of that in the CRISPRi case. This gives a fold
change of activation (AFC) of
AFC =
rfP + rCKCg1P







again with Cg1 specified by Eq. (8) and (9). We are left with an additional
parameter in the activation case, the ratio of activation rC
rf
= rA for a single
target promoter by a bound activator. This is because we cannot assume
zero expression from an un-activated promoter the way we assumed perfect
repression of the bound promoter in CRISPRi – in practice, engineered acti-
vatable CRISPRa promoters are built from weak, but functional, constitutive
core promoters that produce some transcription when unbound. We estimate
an activation ratio of 50:1 based on the optimized dCas9-SoxSR93A activation
system from [23].
5.3. Sensitivity to Parameters
We investigated the robustness of our results to errors in parameters by
subjecting our model to a local, gradient-based sensitivity analysis, using two
summary statistics of CRISPRa performance relative to CRISPRi. We define
the “fold change overperformance” of a pair of CRISPRa/CRISPRi systems
with a specific set of parameters (including a specific number of competing
guides) as the fold change of activation for a CRISPRa system with that set
of parameters divided by the fold change of repression for a CRISPRi system
with that set of parameters.
Fold Change Overperformance(params) =
AFC(params)
RFC(params)
We also measure the advantage in scalability of CRISPRa over a CRISPRi
system with the same parameters with a measure we call “scaling overperfor-
mance”, which we define as the maximum number of competing gRNAs that
the system can tolerate with fold change caused by g1 remaining above 10-
fold for the CRISPRa system, divided by the same number for the CRISPRi
system.
12
.CC-BY 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/719278doi: bioRxiv preprint first posted online Jul. 30, 2019; 
Scaling Overperformance(params) =
max (N) s.t. AFC > 10
max (N) s.t. RFC > 10
For each overperformance measure, we numerically calculate sensitivity
of that measure to each parameter as the derivative of overperformance with
respect to that parameter at our best-guess parameter set. These raw sensi-
tivity values were normalized against parameter scale (i.e., errors in parame-
ter estimation are assumed to be proportional in scale to the values of those
parameters) and overperformance at the best-guess parameter value (so that
sensitivity is given as a relative error).
sensitivity(params) =
params ∗ raw sensitivity(params)
overperformance (params)
For N = 30 competing gRNAs, Ptot = 10 target copies, Ctot = 530
copies of dCas9 (roughly the maximum number an E. coli cell can support
with negligible growth defect), rA = 50, and all other parameters set as in
Table 1, we find the sensitivities of fold change overperformance and scaling
overperformance listed in Tables 3 and 4, respectively.
Parameter Sensitivity (normalized) Description
rA 0.848310 fold change of activation
Ctot 0.716537 Total steady-state dCas pool
α1 0.709052 Transcription rate of g1
Ptot -0.690079 Target promoter concentration
αx -0.679508 Transcription rate of other gRNAs
β -0.029544 δ
K1
, δ =(degradation plus dilution) rate for gRNAs
K 0.026457
Association constant for dCas:gRNA complex
binding to promoter.
Table 3: Sensitivity of fold change overperformance to each parameter.
Unsurprisingly, fold change overperformance is most sensitive to rA, the
fold change of activation for promoters bound to a CRISPR activator. Fold
change overperformance is also somewhat sensitive to Ctot, Ptot, α1, and αx.
We have already shown how CRISPRi and CRISPRa performances change
over realistic values of Ctot and Ptot.
The parameters α1 and αx – the transcriptional speeds of the target
gRNA and competing gRNAs, respectively – are effectively different ways of
13
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Parameter Sensitivity (normalized) Description
rA 1.079925 fold change of activation
Ctot -0.335800 Total steady-state dCas pool
α1 -0.267926 Transcription rate of g1
β 0.267926 δ
K1
, δ =(degradation plus dilution) rate for gRNAs
Ptot 0.207065 Target promoter concentration
K -0.128736
Association constant for dCas:gRNA complex
binding to promoter.
αx -0.000000 Transcription rate of other gRNAs
Table 4: Sensitivity of scaling overperformance to each parameter.
scaling N . Increasing αx changes the concentration of competing guide RNA
in the same way that increasing N does, while changing α1 is equivalent
to changing both αx and Ctot. Therefore, changes to these two variables
are roughly equivalent to shifting the performance curves shown in Figure 1
along the ”# Competing Guides” axis, albeit in a nonlinear way.
Fold change overperformance is relatively unaffected by K and β, which
both incorporate binding constants and are therefore parameters of particu-
larly high uncertainty.
In contrast, scaling overperformance is fairly sensitive to β, though only
somewhat more so than to Ptot (and less than to Ctot, which we can see
from Figure 3 is still not particularly large (remember that overperformance
is a relative measure of the effectiveness of CRISPRa vs CRISPRi). We
are therefore less confident in our ability to quantitatively predict scaling
overperformance than fold change overperformance, but we believe the overall
trend that CRISPRa performs better than CRISPRi under conditions of high
gRNA competition will hold.
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